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Abstract
Background: Testicular germ cell tumors (TGCTs) respond well to cisplatin-based chemotherapy
and show a low incidence of acquired resistance compared to most somatic tumors. The reasons
for these specific characteristics are not known in detail but seem to be multifactorial. We have
studied gene expression profiles of testicular and colon cancer derived cell lines treated with
cisplatin. The main goal of this study was to identify novel gene expression profiles with their
functional categories and the biochemical pathways that are associated with TGCT cells' response
to cisplatin.
Results: Genes that were differentially expressed between the TGCT cell lines vs the (somatic)
HCT116 cell line, after cisplatin treatment, were identified using the significance analysis of
microarrays (SAM) method. The response of TGCT cells was strikingly different from that of
HCT116, and we identified 1794 genes that were differentially expressed. Functional classification
of these genes showed that they participate in a variety of different and widely distributed functional
categories and biochemical pathways. Database mining showed significant association of genes (n =
41) induced by cisplatin in our study, and genes previously reported to by expressed in
differentiated TGCT cells. We identified 37 p53-responsive genes that were altered after cisplatin
exposure. We also identified 40 target genes for two microRNAs, hsa-mir-372 and 373 that may
interfere with p53 signaling in TGCTs. The tumor suppressor genes NEO1 and LATS2, and the
estrogen receptor gene ESR1, all have binding sites for p53 and hsa-mir-372/373. NEO1 and LATS2
were down-regulated in TGCT cells following cisplatin exposure, while ESR1 was up-regulated in
TGCT cells. Cisplatin-induced genes associated with terminal growth arrest through senescence
were identified, indicating associations which were not previously described for TGCT cells.
Conclusion: By linking our gene expression data to publicly available databases and literature, we
provide a global pattern of cisplatin induced cellular response that is specific for testicular cancer
cell lines. We have identified cisplatin-responsive functional classes and pathways, such as the
angiogenesis, Wnt, integrin, and cadherin signaling pathways. The identification of differentially
expressed genes in this study may contribute to a better understanding of the unusual sensitivity
of TGCT to some DNA-damaging agents.
Published: 21 August 2007
Molecular Cancer 2007, 6:53 doi:10.1186/1476-4598-6-53
Received: 4 May 2007
Accepted: 21 August 2007
This article is available from: http://www.molecular-cancer.com/content/6/1/53
© 2007 Duale et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 21
(page number not for citation purposes)
Molecular Cancer 2007, 6:53 http://www.molecular-cancer.com/content/6/1/53Background
Testicular germ cell tumors (TGCTs) are the most com-
mon tumors among young men. Fortunately, they
respond well to cisplatin (Cis-Diamminedichloroplati-
num (II) or CDDP)-based chemotherapy and there is a
low incidence of acquired resistance for TGCT compared
to most somatic tumors. More than 80% of all TGCTs
with metastatic disease are curable using cisplatin-based
chemotherapy [1]. TGCT are histologically classified as
seminomas or non-seminomas, both originating from a
common precursor known as carcinoma in situ (also
known as intratubular germ cell neoplasia of the unclassi-
fied type) [2-4]. TGCT derived cell lines have often been
used as model for studying cisplatin response [5,6]. The
cause of their extreme sensitivity to chemotherapy seems
to be multifactorial. TGCTs are "prone to apoptosis" and
some studies have reported high levels of the pro-apop-
totic Bax protein and low levels of the anti-apoptotic Bcl-
2 protein (high Bax:Bcl-2 ratio), and elevated wild-type
p53 function [7-10]. There are, however, conflicting
reports on the role of the p53 status. The sensitivity
toward cisplatin may also be an inherent property of pri-
mordial germ cells (PGCs) or gonocytes which are likely
precursor cells for TGCTs [11]. Besides cisplatin, TGCTs
are highly sensitive also to other chemotherapeutic drugs
such as etoposide, ifosfamide, bleomycin, and vinblastine
[12]. Similar to these agents, cisplatin is a DNA-damaging
drug; cisplatin binds to form both intra- and inter-strand
cross-links, and is thought to exert its cytotoxic effects
through irreversible binding with DNA. One would hence
expect variation in DNA repair capacities to be of impor-
tance for cell-type specific cisplatin sensitivity. Some stud-
ies have described a reduced ability of TGCT cells to repair
cisplatin-induced DNA lesions, which is associated with a
reduced expression level of several nucleotide excision
repair (NER) proteins [13,14]. Cisplatin-adducts are
removed from DNA mainly by NER [15]. In addition, It
has been suggested that testis specific high-mobility group
domain proteins such as SRY (testis-determining factor
gene) may shield the cisplatin-induced DNA lesions from
DNA repair proteins [16,17].
We have previously reported on DNA repair capacities in
normal male germ cells. NER seems to be low in normal
male germ cells compared to somatic cells [18], whereas
base excision repair (BER) of oxidative lesions appears to
be inefficient in testicular cells from humans but not in
rodents [19]. These properties may have implications for
the sensitivity to chemotherapeutics such as cisplatin, but
are also of interest for the identification of environmental
agent(s). In both cases, the global analysis of the response
of genes after a toxic insult (toxicogenomics) provide an
opportunity to study complex interactions. It is expected
that a given toxicant will induce a distinct pattern of gene
expression within its target cell or tissue, which can be
used to identify and understand (cell type specific) toxic
effects [20-22].
In this study we have analyzed cisplatin-induced gene
expression in two well-characterized human testicular
germ cell tumor (TGCT) derived cell lines (833K and
GCT27) which both are sensitive to cisplatin, and a
human colon carcinoma cell line (HCT116). We further
evaluated the testicular germ cell tumor cells' specificity of
response, by mining available public databases and litera-
ture. The statistical technique SAM was used to identify
signature genes whose mRNA levels were significantly and
differentially expressed between TGCT and HCT116 cells
upon cisplatin treatment. We have identified discrimina-
tory gene expression profiles that distinguish TGCT cells
from the somatic HCT116 cell line. Genes identified to be
significantly expressed were mapped by means of the
Gene Ontology (GO) [23] and the Panther biochemical
pathway [24] to obtain biological interpretations of the
microarray data. We report here the identification of path-
ways and functional categories associated with cellular
response to cisplatin. Besides previously identified path-
ways, we have identified new pathways that are likely to
be relevant for the cisplatin mode of action. We have iden-
tified cisplatin induced p53-responsive, apoptosis-related,
and senescence-like or terminal differentiation associated
genes in TGCT cells. The knowledge extracted from the
gene expression regulation and biological pathways in
this way can be applied to elucidate the unique biology
underlying the specific response of testicular tumors to
cisplatin-based chemotherapy. Furthermore, this infor-
mation may facilitate the identification of toxic com-
pounds interfering with the immature male reproductive
system.
Results
Cell cycle response of cisplatin-exposed cells
Unlike most somatic tumors, even metastatic TGCTs are
usually cured by cisplatin-based chemotherapy. Cisplatin
is a well characterized DNA-reactive agent, and it does not
require metabolic activation. We used TGCT-derived cell
lines in the search for gene expression signatures that
characterize their response to lower doses of cisplatin. The
doses used is in a concentration range reported to be clin-
ically achievable for cisplatin [25]. Two treatment periods
were 24 or 48 h, whereafter cells were immediately har-
vested for RNA isolation. At least two concentration levels
were tested for each cell type; a low concentration that
induced limited cell death and a higher concentration that
induced profound cell cycle arrest in TGCTs (flow cyto-
metric analysis). For 833K and GCT27 these were 0.3 µM
(0.1 µg/ml) and 1.3 µM (0.4 µg/ml), and for HCT116 1.3
µM and 6.7 µM (2.0 µg/ml). The higher doses gave a delay
in S-phase and a clear G2/M-arrest (~70 -80%) in all threePage 2 of 21
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and GCT27 cells (data not shown).
Functional analysis and identification of discriminatory 
gene expression profiles after cisplatin exposure
We have used two-class, unpaired SAM analysis to select
genes whose mean expression level is consistently signifi-
cantly different between TGCT and HCT116 cell lines after
cisplatin treatment. The number of genes that were con-
sistently differentially expressed (FDR < 1% with delta =
3.8) was 1794 genes. 1180 of these genes were over-
expressed in TGCT cells and under-expressed in HCT116
cells, whereas 614 genes were under-expressed in TGCT
cells and over-expressed in HCT116 cells (Additional file
1). When the two TGCT cell lines were compared with
each other, using the same SAM parameters (FDR < 1%,
delta = 3.8), only one gene was found to be significantly
differentially expressed. This also shows that the response
of the two TGCT cells lines is similar and different from
that of HCT116 cells.
Principal Component Analysis (PCA) on average log2-
ratio of the 1794 genes shows a clear difference between
TGCT and HCT116 cells (Figure 1A). The hierarchical
clustering analysis of the top 50 over- and under-
expressed genes from the SAM-identified genes (n = 1794)
is represented in Figure 1B. The clustering dendrogram
indicates that the TGCT cell lines are clustered close to
each other. Examples of some consistently over-expressed
genes in cisplatin exposed TGCT cells are IL1A, EXOC6,
FYN, ANGEL2, BCL2L10, ASCL3, PCDHB5, LOC283075,
ROCK1, and USP6NL;, the under-expressed genes include
LRP6, CDKN2B, MYST4, ZNF174, MLF1, CPT1B, TARSL2,
UCP2, KIAA1160, and MYO1E. The gene expression pro-
files constituted by these altered genes can be used as a
basis for identification of candidate genes that may be
involved in the biology of the specific high sensitivity of
TGCT cells toward cisplatin exposure.
To determine the biological relevance of the SAM-identi-
fied genes, we have investigated their cellular functions
using eGOn v2.0 [26,27] and Panther [24,28]. The eGOn
uses Fisher's exact test and allows determination of signif-
icantly enriched GO terms within a gene set, compared
with the frequency among genes on the array. We corre-
lated SAM-identified genes with the following functional
categories: biological process, molecular function, and cellular
component. This analysis aimed at an understanding of the
effect of the modulation of gene expression on a particular
cellular function. eGOn results represent a global picture
of biological processes, molecular functions and cellular
co-localizations that are significantly enriched following
cisplatin treatment. Sixty-five GO categories were identi-
fied as significantly enriched (p < 0.01) among the genes
identified by SAM as differentially expressed. Figure 2
shows the average gene expression ratios of these gene sets
in each GO term; they were used to construct the heat-
map. The GO terms assigned to the significantly altered
genes are listed in Additional file 2.
The most significantly enriched (p < 0.01) biological process
gene categories include genes related to sensory percep-
tion, cell surface receptor linked signal transduction,
physiological response to stimulus, neurophysiological
process, and potassium ion transport ; genes in these cat-
egories were over-expressed in TGCT cells following cispl-
atin exposure. Significantly enriched (p < 0.01) biological
processes among the under-expressed genes included those
involved in transcription; nucleobase, nucleoside, nucle-
otide and nucleic acid metabolism; sodium ion transport;
and response to pH (Figure 2).
Significantly enriched (p < 0.01) molecular function gene
categories include genes related to olfactory receptor activ-
ity, calcium ion binding, taste receptor activity, and trans-
membrane receptor activity. The gene sets in these GO
categories were up-regulated in TGCT cells following cis-
platin exposure. Significantly enriched molecular functions
among the down-regulated genes include those involved
in DNA binding, channel or pore class transporter activity,
extracellular ligand-gated ion channel activity, specific
RNA polymerase II transcription factor activity, and lig-
and-gated ion channel activity (Figure 2). Taken together,
cisplatin seems to significantly interfere with processes
associated with transcription and DNA metabolism.
To identify biochemical pathways that had been affected
by cisplatin gene expression modulation, we analyzed
SAM-significant genes by Panther [24,28]. Panther uses
the binomial statistics tool to determine over- or under-
representation of Panther classification categories. Pan-
ther determines functional clusters by representation of
individual genes in specific categories relative to all genes
in the same category on the array [24]. The most signifi-
cantly over-represented pathways (p < 0.05) were angio-
genesis, Wnt signaling pathway, inflammation mediated
by chemokine and cytokine signaling pathway, integrin
signalling pathway, PDGF signaling pathway, interleukin
signaling pathway, Huntington disease, Alzheimer dis-
ease-presenilin pathway, cadherin signaling pathway, p53
pathway, TGF-beta signaling pathway, and apoptosis sig-
naling pathway; these are shown in Figure 3. The identi-
fied pathways are over-represented mainly with gene sets
that are up-regulated in TGCT cells following cisplatin
exposure. Panther pathways significantly over-repre-
sented in down-regulated genes in TGCT cells are involved
in TGF-beta signaling pathway, and axon guidance medi-
ated by semaphorins and by Slit/Robo (Figure 3). Inter-
leukin signaling pathway and Huntington disease
pathway were over-represented in both up- and down-reg-Page 3 of 21
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Principle component analysis (PCA) and hierarchical clustering analysis of SAM-identified genesFigure 1
Principle component analysis (PCA) and hierarchical clustering analysis of SAM-identified genes. A) PCA of SAM 
identified genes that discriminate TGCT cells from HCT116 cells (n = 1794); 1180 up-regulated in TGCT cells and 614 genes 
up-regulated in HCT116 cells. Blue dots represent the 1180 up-regulated genes in TGCT cells and the green dots represent 
the 614 up-regulated in HCT116 cells, and vice versa. The complete list from SAM analysis is submitted as Additional file 1. B) 
Hierarchical clustering analysis of the top 50 over- and under-expressed genes from the SAM identified gene list. Genes are 
color coded based on the group they belong to.
1180 over-expressed genes in TGCT 
cells & under-expressed in HCT116 cells 
(blue)
614 under-expressed genes in 
TGCT cells & over-expressed in 
HCT116 cells (green)
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Functional categories affected by cisplatin exposure of TGCT cellsigure 2
Functional categories affected by cisplatin exposure of TGCT cells. Hierarchical clustering analysis of significantly 
enriched (p < 0.01) GO-terms. SAM-identified differentially expressed genes (n = 1794) were grouped into gene sets based on 
common biological processes, molecular functions, or cellular components as assessed by the GO database. The average gene 
expression ratios of the gene sets in each GO term were used to construct the heat-map. Color coding: Over-represented 
GO-terms in the over-expressed gene sets (red), and over-represented terms in the under-expressed gene sets (green).
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Molecular Cancer 2007, 6:53 http://www.molecular-cancer.com/content/6/1/53ulated genes. From this analysis, we have identified new
functional categories and biochemical pathways which
have not previously been shown to be associated with cis-
platin-induced cellular response in TGCT cells.
In silico analysis of significantly altered genes
A search was performed in the publicly available data-
bases in order to compare the gene expression of our SAM-
identified gene list to those reported for other systems. We
used the microarray data from Skotheim et al. (2005)
(GEO accession number GSE1818), which is a study of
germ cell gene expression measured in normal and tumor
human testis biopsies and TGCT cells [29]. They studied
retinoic acid (RA)-induced in vitro differentiation of two
other TGCT cell lines, a pluri-potent NTERA2 cell line, and
a nulli-potent 2102Ep cell line (NTERA2 cells differentia
upon RA treatment whereas 2102Ep does not). We con-
ducted similarity searches between our SAM-identified
gene expression data and microarray data from GSE1818
(only the microarray data from RA-treated and untreated
TGCT cells (NTREA2 and 2102Ep) were used). We
selected 79 genes that showed similar expression patterns
in our cisplatin treated as in the RA-treated the TGCT cell
line NTREA2. Of those genes, 41 were up-regulated and
38 were down-regulated genes in TGCT cells following cis-
platin exposure. Figure 4 shows hierarchical clustering
analysis of these 79 genes. By visual inspection of the
heat-map (Figure 4), we observed that cisplatin treated
TGCT cells and RA-induced differentiated TGCT cells were
clustered together, and they showed similar expression
pattern.
From the database mining comparison, we conclude that
cisplatin exposed TGCT cells and RA-induced differenti-
ated TGCT cells appear to share distinct gene expression
patterns. A significant number of the genes altered in
response to cisplatin were among those highly expressed
also in the RA-induced differentiated TGCT cells; this is
unlike the pattern for the somatic HCT116 cell line and
the undifferentiated TGCT cells [29].
In silico prediction of p53
The tumor suppressor gene p53 is an important transcrip-
tion factor activated by DNA damage. Although several
reports underline the importance of p53-siganling path-
way in cisplatin response in TGCT cells, other studies have
reported a partially non-functional p53-signaling path-
way [30-37]. With the hypothesis that p53-associated tar-
get genes are heavily involved in cisplatin response, we
analyzed the SAM-identified gene list with respect to
genes possessing a predicted or known p53 binding site in
the promoter region. For this purpose we searched the lit-
erature, the Transcriptional regulatory element database
(TRED) [38], and Transcription factor binding profile
database (JASPAR) [39,40]. Table 1 shows that 37 p53 tar-
get genes were found in our gene list, of which 26 genes
were up-regulated and 11 genes were down-regulated in
TGCT cells upon cisplatin exposure. All of these target
genes have consensus p53-responsive elements upstream
of their predicted transcriptional start site, according to
the JASPAR-database.
Recently, Voorhoeve and co-workers identified two
microRNAs (miRNA), hsa-mir-372 and hsa-mir-373 that
are highly expressed in TGCTs and TGCT derived cell
lines, and it was reported that these miRNAs suppressed
elements of the p53 pathway in TGCT cells. We used the
target prediction programs, PicTar and TargetScan 3.1
[41,42], to identify possible targets of hsa-mir-372 and
373. We found that 40 genes (24 up-regulated and 16
down-regulated in TGCT cells), among our SAM-identi-
fied gene list were predicted target genes for both hsa-mir-
372 and 373 (Table 2).
From the SAM-identified gene list we found that Neo-
genin homolog 1 (NEO1), large tumor suppressor
homolog 2 (LATS2) and Estrogen receptor 1 (ESR1) were
the only genes that have the predicted binding sites for
both p53 and hsa-mir-372 and 373. NEO1 and LATS2
were down-regulated in the TGCT cells cisplatin exposure,
while ESR1 was up-regulated.
Apoptosis-related genes altered following cisplatin 
exposure
Among the SAM-identified genes, we found 24 apoptosis-
related genes (Table 3). In the TGCT cells, the cisplatin
exposure led to increased gene expression of IL1A,
BCL2L10, BCL2L13, MPO, CCL2, CASP8, IL2, CARD6,
P53AIP1, BAG5, DOCK1, CAPN1, CAPN2, STK17B and
GML. However, the gene expression levels of 9 apoptosis-
related genes, BAG4, BIRC7, MXD4, APITD1, ING2,
PAWR, PDCD6, BCL2L11 and TNFAIP8, were significantly
decreased in the cisplatin exposed TGCT cells.
Cellular senescence-related genes altered following 
cisplatin exposure
Terminal differentiation or senescence is an important
response to low doses of chemotherapy agents. The over-
expression of several male germ cell specific (testis spe-
cific) genes in TGCT cells may indicate differentiation in
response to cisplatin. We hence performed a literature
mining in order to identify reported senescence-related
genes in other systems. Among the SAM-identified genes,
5 genes proved to be in common with those reported by
Schwarze and co-workers who studied gene expression in
terminally differentiated human prostate epithelial cells
(HPECs) compared to proliferating cells [43]. By compar-
ing with the Chang et al. (2001) study, in which gene
expression in senescent relative to proliferating cells
treated with doxorubicin [44] were studied, we identifiedPage 6 of 21
(page number not for citation purposes)
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Panther pathways affected by cisplatin exposure of TGCT cellsFigur  3
Panther pathways affected by cisplatin exposure of TGCT cells. Significantly enriched (p < 0.05) Panther pathways in 
over- and under-expressed genes following cisplatin exposure. Blue bars represent the number of over-expressed genes in the 
pathway, green bars the number of under-expressed genes.
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Hierarchical clustering analysis of 79 genesFigure 4
Hierarchical clustering analysis of 79 genes. These genes have been identified as being commonly expressed in microar-
ray data from GSE1818, and in our SAM identified genes. The dendrogram shows that cisplatin exposed TGCT cells and RA-
treated differentiated TGCT cells are closely clustered. Genes are colored coded according to their expression patterns.
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Gene NameScore(d) Biological Process
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Table 1: List of p53 responsive genes (n = 37). 26 genes were up-regulated and 11 genes were down-regulated in the TGCT cells 
following cisplatin exposure
UniGene ID Gene Name Description SAM Score(d) Referance (a) p53 binding motifs (b)
A) 26 p53 target genes that are up-regulated in TGCT cells and down-regulated in HCT116 cells
Hs.306322 NAV3 Neuron navigator 3 7.60 2 +
Hs.553498 PIK3CA Phosphoinositide-3-kinase, catalytic, alpha 
polypeptide
6.63 1 +
Hs.196054 HDAC9 Histone deacetylase 9 6.44 2 +
Hs.395482 PTK2 PTK2 protein tyrosine kinase 2 6.30 2 +
Hs.501778 TRIM22 Tripartite motif-containing 22 6.11 2,3&4 +
Hs.160871 PTPRO Protein tyrosine phosphatase, receptor type, 
O
5.96 2 +
Hs.495473 NOTCH1 Notch homolog 1, translocation-associated 
(Drosophila)
5.73 2 +
Hs.591292 GPR87 G protein-coupled receptor 87 5.59 3 +
Hs.13291 CCNG2 Cyclin G2 5.27 2 +
Hs.65029 GAS1 Growth arrest-specific 1 5.13 1 +
Hs.592020 IGF1R Insulin-like growth factor 1 receptor 5.09 1 +
Hs.591630 CASP8 Caspase 8, apoptosis-related cysteine 
peptidase
5.04 1 +
Hs.138211 MAPK8 Mitogen-activated protein kinase 8 5.03 1 +
Hs.89679 IL2 Interleukin 2 5.02 1 +
Hs.93842 STARD4 START domain containing 4, sterol 
regulated
4.95 2 +
Hs.326035 EGR1 Early growth response 1 4.90 1 +
Hs.40582 CDC14B CDC14 cell division cycle 14 homolog B (S. 
cerevisiae)
4.52 1 +
Hs.634224 PIAS2 Protein inhibitor of activated STAT, 2 4.43 2 +
Hs.648190 ASTN2 Astrotactin 2 V-erb-a erythroblastic 
leukemia viral oncogene homolog 4
4.34 2 +
Hs.390729 ERBB4 (avian) 4.28 2 +
Hs.476018 CTNNB1 Catenin (cadherin-associated protein), beta 
1, 88 kDa
4.22 1 +
Hs.591179 DGKE Diacylglycerol kinase, epsilon 64 kDa 4.21 1 +
Hs.35947 MBD4 Methyl-CpG binding domain protein 4 SWI/
SNF related, matrix associated, actin 
dependent
4.05 1 +
Hs.534350 SMARCB1 regulator of chromatin, subfamily b, member 
1
4.03 2 +
Hs.545196 GML GPI anchored molecule like protein 3.41 1&2 +
Hs.208124 ESR1* Estrogen receptor 1 3.04 1 +
B) 11 p53 target genes that are down-regulated in TGCT cells and up-regulated in HCT116 cells
Hs.388613 NEO1* Neogenin homolog 1 (chicken) -7.00 2 +
Hs.124922 LRMP Lymphoid-restricted membrane protein -5.99 4 +
Hs.168132 IL15 Interleukin 15 -5.77 1 +
Hs.256126 BIRC7 Baculoviral IAP repeat-containing 7 (livin) -5.59 1 +
Hs.76171 CEBPA CCAAT/enhancer binding protein (C/EBP), 
alpha
-5.45 1 +
Hs.78960 LATS2* LATS, large tumor suppressor, homolog 2 
(Drosophila)
-4.54 2 +
Hs.271955 TNFAIP8 Tumor necrosis factor, alpha-induced 
protein 8
-4.46 2 +
Hs.397465 HIPK2 Homeodomain interacting protein kinase 2 -4.37 1 +
Hs.291363 CHEK2 CHK2 checkpoint homolog (S. pombe) -4.26 1 +
Hs.508423 ABCC4 ATP-binding cassette, sub-family C (CFTR/
MRP), member 4 Solute carrier family 7 
(cationic amino acid transporter, y+
-4.06 1 +
Hs.334848 SLC7A6 system), member 6 -3.95 4 +
a) Predicted and known p53 target genes based on following references (1) Zhao et al. (2005) [38], (2) Wei et al. (2006) [80], (3) Kerley-Hamilton et al. 
(2005) [35]and (4) Barenco et al. (2006) [81]). b) These genes have a consensus p53-responsive element (MA0106) upstream of their predicted 
transcriptional start site according to the JASPAR database [39,40].* NEO1, LATS2 and ESR1 are the only target genes common for both p53 and hsa- 
mir-372 and 373.
Molecular Cancer 2007, 6:53 http://www.molecular-cancer.com/content/6/1/533 genes in common in our SAM-identified gene list. We
have observed up-regulation of some testis specific genes
such as SPAM1, SPATA22, TCAM1, SPAG17, SOX17 and
SOX7 in TGCT cells. Table 4 shows 29 senescence or dif-
ferentiation related genes induced in response to cisplatin
in this study.
Validation of microarray data by real-time PCR
The results obtained from the microarray data analysis
revealed an altered transcription of many genes following
cisplatin treatment. To verify their expression, quantita-
tive real-time RT-PCR was performed using the same RNA
as that used in the microarray analysis. Eight selected
genes from our SAM-identified genes were analyzed. Of
those, GAS1, HAP1, and BCL2L-10 were up-regulated in
TGCT cells and down-regulated in HCT116 cells, while
NEO1, DICER1, IL6ST, SSBP2 and NFRKB were down-
regulated in TGCT cells and up-regulated in HCT116 cells.
The quantitative real-time PCR results for these genes were
in good correlation (same direction) with the microarray
results (Figure 5).
Discussion
Microarray technology may facilitate the analysis of the
mechanisms of action of drugs. The mRNA expression
profile of drug-treated cells can readily be compared with
untreated control cells to reveal those genes that have
undergone a change in response to drug treatment. The
main goals of this study were to identify novel gene
expression profiles with their functional categories and
the biochemical pathways that are associated with the
TGCT cells' response to cisplatin-induced DNA-damage.
The strategy was to identify statistically significantly
altered genes that differentiate two testicular germ cell
tumor cell lines from a somatic colon tumor cell line
(HCT116) by using the SAM method. SAM is a robust sta-
tistical method that has been specifically developed for
microarray data analysis [45]. By using two-class,
unpaired SAM analysis, we have identified many genes
that discriminate TGCT cells from HCT116 cells. The anal-
ysis of the SAM-identified (n = 1794) genes by unsuper-
vised hierarchical clustering [46], showed that we could
readily group TGCT cells based solely on the patterns of
the their expression. Moreover, the Principal Component
Analysis also demonstrated that there were clear gene
expression pattern differences between TGCT and
HCT116 cells used in the study. However, the task of
organizing the clusters of significantly expressed genes for
further biological interpretation and determining what
kind of genes or pathways that are involved in mediating
the effects of cisplatin remain as main challenges. Plati-
num based compounds are routinely used in the treat-
ment of TGCTs in combination with bleomycin and
etoposide. It is possible that these and other chemoter-
apeutics may interfere with the same pathways as we have
identified using cisplatin; however, to our knowledge no
relevant systematic study of expression patterns in vitro
have been presented.
We have addressed the biological relevance of the differ-
entially expressed genes through analysis of the GO terms
and biochemical pathways utilizing eGOn [26,27] and
Panther [24,28]. The result of these analyses are summa-
rized in Figure 2 and 3. Interestingly, the most over-repre-
sented biological processes comprising the up-regulated
genes were sensory perception, cell surface receptor linked
signal transduction, physiological response to stimulus,
neurophysiological process, and potassium ion transport.
Among the down-regulated genes, there were genes
related to transcription; nucleobase, nucleoside, nucle-
otide and nucleic acid metabolism; sodium ion transport;
and response to pH. Predominating biochemical path-
ways found to be significantly over-represented in TGCT
cells were angiogenesis, Wnt signaling pathway, inflam-
mation mediated by chemokine and cytokine signaling
pathway, integrin signalling pathway, PDGF signaling
pathway, interleukin signaling pathway, Huntington dis-
ease, Alzheimer disease-presenilin pathway, cadherin sig-
naling pathway, p53 pathway, TGF-beta signaling
pathway, and apoptosis signaling pathway. Taken
together, we have identified new functional classes and
pathways that were not previously known to be associated
with cisplatin treatment.
We compared our SAM-identified genes with publicly
available micoarray data from Skotheim et al. (2005).
These authors reported on germ cell gene expression in
normal and tumor human testis biopsies; they also stud-
ied TGCT cells after RA treatment [29]. Among our cispla-
tin responsive genes, a subpopulation of 41 genes was
identified that represents genes being over-expressed both
in cisplatin exposed TGCT cells, and also in the RA-
induced differentiated TGCT cell line [29]. The clustering
dendrogram (Figure 4) shows that cisplatin responsive
genes in TGCT cells and RA-induced differentiated TGCT
cells were categorized into close branches and they had a
similar expression pattern. Genes involved in GO catego-
ries such as cell adhesion, development, and sperma-
togenesis were abundant among the 41 highly expressed
genes. RA-induced growth arrest of tumor cells is assumed
to result from induction of differentiation and this has
been corroborated by the appearance of differentiation
specific markers in RA-treated cells [47]. Among the 41
over-expressed genes in differentiated and cisplatin
exposed TGCT cells (Figure 4), there are genes that may be
used as TGCT terminal differentiation markers.
The biochemical mechanisms underlying the extreme sen-
sitivity of TGCTs for cisplatin are still partly unknown.
Analysis of potential parameters in cisplatin sensitivity,Page 10 of 21
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Molecular Cancer 2007, 6:53 http://www.molecular-cancer.com/content/6/1/53Table 2: List of SAM-identified genes (n = 40) predicted as target for hsa-mir-372 and 373
UniGene ID Gene Name Description SAM score(d)
A) 24 miR-372&373 target genes that are up-regulated in TGCT cells and down-regulated in HCT116 cells
UniGene ID Gene_symbol Gene_description Score(d)
Hs.280604 PPP3R1 Protein phosphatase 3 (formerly 
2B), regulatory subunit B, 19 kDa, 
alpha isoform
6.48
Hs.201034 NTN4 Netrin 4 6.35
Hs.126497 AEBP2 AE binding protein 2 6.18
Hs.373857 KLF12 Kruppel-like factor 12 6.06
Hs.514242 PLEKHM1 Pleckstrin homology domain 
containing, family M (with RUN 
domain) member 1
5.93
Hs.499489 MARCH8 Membrane-associated ring finger 
(C3HC4) 8
5.63
Hs.349150 PURB Purine-rich element binding 
protein B
5.55
Hs.25960 MYCN V-myc myelocytomatosis viral 
related oncogene, neuroblastoma 
derived (avian)
5.25
Hs.474536 MTMR3 Myotubularin related protein 3 5.24
Hs.291623 TAOK2 TAO kinase 2 5.24
Hs.271341 RABGAP1 RAB GTPase activating protein 1 5.13
Hs.134221 MBNL2 Muscleblind-like 2 (Drosophila) 4.92
Hs.520187 PYCR2 Pyrroline-5-carboxylate reductase 
family, member 2
4.78
Hs.490347 MKRN1 Makorin, ring finger protein, 1 4.75
Hs.191179 RAB11FIP1 RAB11 family interacting protein 1 
(class I)
4.67
Hs.567754 MIER3 Mesoderm induction early 
response 1, family member 3
4.48
Hs.4779 GATAD2B GATA zinc finger domain 
containing 2B
4.34
Hs.159430 FNDC3B Fibronectin type III domain 
containing 3B
4.20
Hs.632239 MNT MAX binding protein 4.16
Hs.591552 RAB6A RAB6A, member RAS oncogene 
family
4.15
Hs.434961 ATXN1 Ataxin 1 4.06
Hs.149261 RUNX1 Runt-related transcription factor 1 
(acute myeloid leukemia 1; aml1 
oncogene)
3.69
Hs.497148 RGL1 Ral guanine nucleotide dissociation 
stimulator-like 1
3.19
Hs.208124 ESR1* Estrogen receptor 1 3.04
B) 16 miR-372&373 target genes that are down-regulated in TGCT cells and up-regulated in HCT116 cells
Hs.293798 ZNF436 Zinc finger protein 436 -7.05
Hs.388613 NEO1* Neogenin homolog 1 (chicken) -7.00
Hs.374097 IRF2 Interferon regulatory factor 2 -6.13
Hs.122927 RSNL2 Restin-like 2 -6.09
Hs.514308 FAM117A Family with sequence similarity 
117, member A
-5.92
Hs.444213 TLE4 Transducin-like enhancer of split 4 
(E(sp1) homolog, Drosophila)
-5.92
Hs.428027 PBX3 Pre-B-cell leukemia transcription 
factor 3
-5.78
Hs.511316 GABPB2 GA binding protein transcription 
factor, beta subunit 2
-5.52
Hs.529044 RAB22A RAB22A, member RAS oncogene 
family
-5.45
Hs.434993 RBJ Ras-associated protein Rap1 -5.28
Hs.496138 IQSEC2 IQ motif and Sec7 domain 2 -4.70
Hs.78960 LATS2* LATS, large tumor suppressor, 
homolog 2 (Drosophila)
-4.54Page 11 of 21
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Molecular Cancer 2007, 6:53 http://www.molecular-cancer.com/content/6/1/53including cellular detoxification mechanisms such as the
glutathione and the metallothionein systems, platinum
accumulation, DNA platination and repair, p53 status,
and expression of Bcl-2 family proteins, have not been
able to fully explain the inherent sensitivity of testicular
tumors [11]. The p53 transcription factor is the key gate-
keeper in the cellular response to stress signals. Different
types of stress result in different post-translational modi-
fications of p53 that lead to one of three different types of
cellular response: cell cycle arrest, cellular senescence, or
apoptosis [48,49]. There are conflicting reports on the role
of p53 in cisplatin sensitivity of TGCTs. Several studies
suggest that p53 is important [30-32], whereas other stud-
ies have shown that p53 status did not relate directly to
the sensitivity of TGCT cells to cisplatin [33,34]. From lit-
erature and database mining, we found 37 p53 responsive
genes in our SAM-identified gene list (Table 1). Func-
tional classification of these 37 genes revealed that they
were widely distributed among several functional catego-
ries; this is in agreement with the global gene regulation
effects of p53. Kerley-Hamilton and co-workers have
shown that TGCT cells have a specific p53-dependent
transcriptional response to cisplatin treatment. They con-
cluded that p53 is an important target of cisplatin-medi-
ated gene expression and cytotoxicity in TGCT cells [35].
In our system, cisplatin exposure resulted in very high p53
phosphorylation, in the TGCT cells compared to the
somatic cells such as HCT116 and MCF-7 (data not
shown). This suggests that the signaling pathways
upstream of p53 are highly responsive to cisplatin. It
appears that the p53 signaling pathway and the feedback
mechanisms controlling this pathway play an important
role in the TGCT response toward cisplatin treatment.
Although testicular germ cell tumors exhibit wild-type
p53, some studies indicate that p53 is non-functional or
only partly functional. The newly discovered microRNAs;
hsa-mir-372 and 373, have been reported to be over-
expressed in TGCT cells but not in normal testis tissues.
These miRNAs do not function by simply down-regulat-
ing p53 itself, but they block p53-mediated CDK2 (cyclin-
dependent kinase 2) inhibition possibly through direct
inhibition of the tumor suppressor gene LATS2 (large
tumor suppressor homolog 2) [36]. Microarray analysis of
hsa-mir-372/373-expressing cells has shown that LATS2, a
known inhibitor of CDK2, was down-regulated, and the 3'
UTR of LATS2 was shown to harbor predicted hsa-mir-
372/373 binding sites. Inhibition of LATS2 expression by
hsa-mir-372/373 relieves CDK2 from repression allowing
continued cellular proliferation in the presence of acti-
vated Ras [36,50]. In this study, we observed down-regu-
lation of LATS2 expression in TGCT cells following
cisplatin exposure (Table 1 and 2).
It has been reported that specific miRNAs contribute to
the regulation of cellular differentiation, proliferation and
apoptosis. The expression of miRNAs is highly specific for
tissues and developmental stages. Little is known about
the regulation of miRNA [41,51,52]. The target prediction
programs, PicTar [41] and TargetScan 3.1 [42], were used
to identify possible targets of hsa-mir-372 and 373. We
have identified 29 genes that were predicted target genes
for both hsa-mir-372 and 373. As shown in Table 1 and 2,
NEO1, LATS2 and ESR1 are the only predicted target gene
for both hsa-mir-372 and 373 and p53; the 3' UTR of
NEO1, LATS2 and ESR1 have potential hsa-mir-372 and
373 binding sites. NEO1 is functionally categorized as a
tumor-suppressor gene and may be involved as a regula-
tory protein in the transition of undifferentiated prolifer-
ating cells to their differentiated state. ESR1 belongs to the
nuclear hormone receptor family and is involved in the
regulation of eukaryotic gene expression, affecting cellular
proliferation and differentiation in target tissues. In our
study, we observed that NEO1 and LATS2 were down-reg-
ulated in the TGCT cells, while ESR1 was up-regulated.
Since NEO1 and LATS2 are tumor-suppressor genes and at
the same time target genes for p53 and hsa-mir-372 and
373, both hsa-mir-372 and 373 may suppress the p53
pathway by destabilizing NEO1s and LATS2s transcript
and/or by inhibiting their translation.
In our study, DICER1 was down-regulated in TGCT cells
after cisplatin exposure (Figure 5). This may explain the
observed up-regulation of some of the hsa-mir-372/373
predicted target genes in TGCT cells (Table 2). Several
reports have suggested that loss of Dicer1 causes embry-
onic lethality and loss of stem cell population [53]. Other
reports suggest that Dicer1 participates in multiple biolog-
ical processes, ranging from stem cell differentiation to
maintenance of centromeric heterochromatin structure
[54]. Cisplatin-induced down-regulation of DICER1 may
repress the oncogenic properties of hsa-mir-372/373. It
has been reported that these miRNAs regulate pathways
Hs.269592 CC2D1A Coiled-coil and C2 domain 
containing 1A
-4.21
Hs.521083 HRBL HIV-1 Rev binding protein-like -4.19
Hs.469658 BCL2L11 BCL2-like 11 (apoptosis facilitator) -4.08
Hs.299315 DPYSL5 Dihydropyrimidinase-like 5 -3.93
NEO1, LATS2 and ESR1 are the only target genes in common for both p53 and hsa-mir-372 and -373.
Table 2: List of SAM-identified genes (n = 40) predicted as target for hsa-mir-372 and 373 (Continued)Page 12 of 21
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Quantitative real-time PCR validation of microarray resultsFigure 5
Quantitative real-time PCR validation of microarray results. Validation of selected 8 SAM-identified genes by quanti-
tative real-time PCR. BCL2L10, HAP1 and GAS1 were up-regulated in TGCT cells and down-regulated in HCT116 cells follow-
ing cisplatin exposure. DICER1, NEO1, IL6ST, NFRKB and SSBP2 were up-regulated in HCT116 cells and down-regulated in 
TGCT cells. The bars indicate the mean +/- S.E.M.
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Table 3: List of apoptosis-related genes (n = 24). 15 up-regulated and 9 down-regulated genes in TGCT cells following cisplatin 
exposure
UniGene ID Gene Name Description SAM Score(d) Function
A) 15 apoptosis-related genes that are up-regulated in TGCT cells and down-regulated in HCT116 cells
Hs.1722 IL1A Interleukin 1, alpha 8.62 anti-apoptosis
Hs.283672 BCL2L10 BCL2-like 10 (apoptosis 
facilitator)
8.03 anti-apoptosis
Hs.631672 BCL2L13 BCL2-like 13 (apoptosis 
facilitator)
6.51 Regulation of apoptosis
Hs.458272 MPO Myeloperoxidase 5.96 anti-apoptosis
Hs.303649 CCL2 Chemokine (C-C motif) 
ligand 2
5.78 anti-apoptosis
Hs.591630 CASP8 Caspase 8, apoptosis-
related cysteine peptidase
5.04 apoptotic program
Hs.89679 IL2 Interleukin 2 5.02 anti-apoptosis
Hs.200242 CARD6 Caspase recruitment 
domain family, member 6
4.83 regulation of apoptosis
Hs.160953 P53AIP1 P53-regulated apoptosis-
inducing protein 1
4.65 apoptosis
Hs.5443 BAG5 BCL2-associated 
athanogene 5
4.57 anti-apoptosis
Hs.350899 CAPN2 Calpain 2, (m/II) large 
subunit
4.45 proteolysis and peptidolysis
Hs.159195 DOCK1 Dedicator of cytokinesis 
1
4.33 Apoptosis
Hs.521800 CAPN1 Calpain 1, (mu/I) large 
subunit
3.97 proteolysis and peptidolysis
Hs.88297 STK17B Serine/threonine kinase 
17b (apoptosis-inducing)
3.62 apoptosis
Hs.545196 GML GPI anchored molecule 
like protein
3.41 apoptosis
B) 9 apoptosis-related genes that are down-regulated in TGCT cells and up-regulated in HCT116 cells
Hs.194726 BAG4 BCL2-associated 
athanogene 4
-6.33 anti-apoptosis
Hs.256126 BIRC7 Baculoviral IAP repeat-
containing 7 (livin)
-5.59 anti-apoptosis
Hs.102402 MXD4 MAX dimerization 
protein 4
-5.59 negative regulation of cell 
proliferation
Hs.412311 APITD1 Apoptosis-inducing, 
TAF9-like domain 1
-5.23 arole in a cell death 
pathway
Hs.107153 ING2 Inhibitor of growth family, 
member 2
-5.07 P53-dependent apoptotic 
pathways
Hs.643130 PAWR PRKC, apoptosis, WT1, 
regulator
-4.99 apoptosis
Hs.379186 PDCD6 Programmed cell death 6 -4.79 Induction of apoptosis
Hs.271955 TNFAIP8 Tumor necrosis factor, 
alpha-induced protein 8
-4.46 anti-apoptosis
Hs.469658 BCL2L11 BCL2-like 11 (apoptosis 
facilitator)
-4.08 apoptosis
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Table 4: Terminal differentiation or senescence related genes (n = 29) induced in TGCT cells following cisplatin exposure
UniGene ID Gene Name Description SAM Score(d)
A) 5 genes from Schwarze et al (2002)
Hs.1722 IL1A Interleukin 1, alpha 8.62
Hs.138211 MAPK8 Mitogen-activated protein kinase 8 5.03
Hs.484551 CPM Carboxypeptidase M 4.88
Hs.504877 ARHGDIB Rho GDP dissociation inhibitor 
(GDI) beta
4.57
Hs.89649 EPHX1 Epoxide hydrolase 1, microsomal 
(xenobiotic)
4.52
B) 3 genes from Chang et al (2001)
Hs.135646 ELF1 E74-like factor 1 (ets domain 
transcription factor)
5.47
Hs.134221 MBNL2 Muscleblind-like 2 (Drosophila) 4.92
Hs.224012 JAG1 Jagged 1 (Alagille syndrome) 4.00
C) 6 Testis-specific genes
Hs.98367 SOX17 SRY (sex determining region Y)-
box 17
6.36
Hs.351068 SPATA22 Spermatogenesis associated 22 6.23
Hs.528821 SPAG17 Sperm associated antigen 17 5.29
Hs.121494 SPAM1 Sperm adhesion molecule 1 (PH-
20 hyaluronidase, zona pellucida 
binding)
4.94
Hs.213194 SOX7 SRY (sex determining region Y)-
box 7
4.84
Hs.629177 TCAM1 Testicular cell adhesion molecule 1 
homolog (mouse)
4.67
D) 2 Germ cell development related genes
Hs.632137 CUGBP1 CUG triplet repeat, RNA binding 
protein 1
4.78
Hs.436445 OSGIN2 Oxidative stress induced growth 
inhibitor family member 2
4.59
E) Other differentiation or senescence related genes (n = 13)
Hs.119693 PCDHB5 Protocadherin beta 5 7.92
Hs.489142 COL1A2 Collagen, type I, alpha 2 6.48
Hs.372946 LOC440895 Similar to LIM and senescent cell 
antigen-like domains 3
5.98
Hs.55999 NKX3-1 NK3 transcription factor related, 
locus 1 (Drosophila)
5.52
Hs.54473 NKX2-5 NK2 transcription factor related, 
locus 5 (Drosophila)
5.08
Hs.154210 EDG1 Endothelial differentiation, 
sphingolipid G-protein-coupled 
receptor, 1
4.99
Hs.645216 IGFBP7 Insulin-like growth factor binding 
protein 7
4.99
Hs.522805 CD99L2 CD99 molecule-like 2 4.45
Hs.234763 NKX2-8 NK2 transcription factor related, 
locus 8 (Drosophila)
4.45
Hs.274313 IGFBP6 Insulin-like growth factor binding 
protein 6
4.14
Hs.528847 MYADML Myeloid-associated differentiation 
marker-like
3.99
Hs.555902 DDEF2 Development and differentiation 
enhancing factor 2
3.88
Hs.106015 DDEF1 Development and differentiation 
enhancing factor 1
3.87
Molecular Cancer 2007, 6:53 http://www.molecular-cancer.com/content/6/1/53controlled by classic tumor suppressors and oncogenes
including p53, MYC and RAS [36,55].
Many p53 target genes were up-regulated in TGCT cells
following cisplatin exposure in this study. However, the
functionality of specific parts of the p53-dependent path-
way may be suppressed through miRNA repression of
some of the p53 target genes, such as NEO1 and LATS2.
Induction of apoptosis after exposure to cisplatin suggests
that TGCT cells may already be primed to undergo pro-
grammed cell death [56]. Many genes in the apoptosis sig-
naling pathway that take part in both the mitochondrial
(intrinsic) pathway and the death receptor (extrinsic)
pathway were engaged. Several apoptosis-related genes
were affected in TGCT cells following cisplatin exposure
(Table 3). The sensitivity of normal testicular cells to
apoptotic stimuli [57] suggests that the unique respon-
siveness of TGCTs to cisplatin-based chemotherapy may
represent inherent biological characteristics of normal
germ cells and TGCT cells.
The non-caspase proteases, Calpain 1 (CAPN1) and Cal-
pain 2 (CAPN2) take part in caspase-independent cell
death pathway; they were up-regulated in TGCT cells after
cisplatin exposure. Molecules involved in alternative
forms of cell death have not yet been exactly defined, and
non-caspase proteases such as calpains have also been
taken into consideration as important for the response to
cytotoxic therapy [58]. There might be a interaction
between the mitochondrial, the death receptor and the
caspase-independent cell death pathways. A cross-talk
between these pathways may result in rapid and efficient
induction of apoptosis in TGCT cells. Del Bello and co-
workers recently reported that there is a cross-talk between
calpain and caspase-3/-7 in cisplatin-induced apoptosis
and that calpain activation is an early event in apoptosis
[59].
Chemotherapy can induce a variety of anti-proliferative
responses, including terminal growth arrest through
senescence and cell death by mitotic catastrophe. Several
cell lines treated with DNA-damaging agents have shown
features of senescence, including the expression of senes-
cence marker SA-β-gal (senescence-associated β-galactosi-
dase). Other studies have identified a number of genes
whose expression was increased or decreased in tumor
cells during development of a senescent phenotype after
treatment with DNA-damaging agents [43,60,61]. Among
different classes of anticancer agents, the senescent phe-
notype is induced most strongly by DNA-damaging agents
such as doxorubicin, aphidicolin, cisplatin, etoposide and
ionizing radiation [62,63].
TGCT cells treated with low doses of cisplatin may
undergo growth arrest, showing features of differentia-
tion. The cisplatin doses used in our study may induce
senescence-like growth arrest in TGCT cells. We observed
significant enrichment of genes belonging to functional
categories and biochemical pathways associated with dif-
ferentiation, such as motility, Alzheimer disease pathway,
and integrin signalling pathway. Chang and co-workers
reported that genes induced in senescent cells were
involved in cell adhesion, cell-cell contact, integrin signal-
ing pathway, and Alzheimer disease pathway [44]. Senes-
cent cells show permanent growth arrest and express
markers associated with terminal differentiation. Consist-
ent with this phenotype, we observed cisplatin induction
of 6 testis-specific genes, SPAM1, SPATA22, TCAM1,
SPAG17, SOX17 and SOX7 (Table 4). Other senescence
associated genes such as EDG1, LOC440895, MYADML,
DDEF1 and DDEF2 were also up-regulated in TGCT cells.
The growth arrest that characterizes cellular senescence-
like phenotype may be induced by lower doses of drugs or
differentiating agents, and induction of cell death is gen-
erally associated with higher drug doses. Tumor cell lines
were reported to express senescence-specific genes and to
undergo terminal growth arrest after treatment with anti-
cancer agents that affect DNA structure [62-65]. Several
reports have suggested the cyclin-dependent kinase inhib-
itor (p21) and genes downstream from p53 to mediate
the growth arrest observed at senescence in non-trans-
formed cells. However, the level of p21 in cisplatin
exposed TGCT cells is very low [66]. Other genes, includ-
ing the Cdk inhibitor p16INK4a, are involved in the
maintenance of senescence [43,67-69]. In addition to
senescence and apoptosis, another major anti-prolifera-
tive effect of DNA-damaging agents is cell death through
mitotic catastrophe [70]. The mutual effects of apoptosis,
senescence-like phenotype, and mitotic catastrophe in
tumors in response to treatment are illustrated by studies
in which inhibition of apoptosis was shown to increase
mitotic catastrophe, senescence, or both [71-73]. Studies
also suggest that members of the insulin-like growth fac-
tor, IGF2 and its IGF-binding proteins (e.g., IGFBP5), con-
stitute another senescence pathway [43,69]. In our study,
we observed an induction of IGFBP6 and IGFBP7 in TGCT
cells after cisplatin exposure (Table 4). From literature
mining, we found 29 senescence-related genes highly
expressed in TGCT cells following cisplatin exposure
(Table 4). This comparison of our SAM-identified genes
with senescence associated genes in the literature suggests
the presence of senescence-specific genes which are con-
served among cells derived form different tissues. There-
fore, senescence-specific genes appear to be useful in the
identification of cells displaying the terminal arrest and
morphology associated with senescence. Knowledge
about patterns of gene expression in senescent cells mayPage 16 of 21
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the development of new anticancer drugs.
The results of real-time PCR confirmed in general the gene
expression results obtained by microarray analysis for the
8 selected genes (Figure 5). There were slight variations
with respect to the magnitude of the relative expression,
but the relative expression of the two methods was con-
sistently in the same direction. The independent quantita-
tive real-time PCR analysis further verified the validity of
microarray results. Moreover, the real-time PCR measure-
ments provide further support to the claim that the rela-
tive signal intensity from a microarray is a good
quantitative measure of gene expression.
Conclusion
This study has shown alterations of gene expression in
TGCT cells treated with cisplatin. The systematic approach
used proved to be valuable for identifying hundreds of
alterations in gene expression, allowing identification of
new functional classes and pathways which have not pre-
viously been shown to be associated with cisplatin-
induced cellular response in TGCT cells. By linking our
gene expression data to other publicly available microar-
ray data, we have further identified gene expression pat-
terns for cisplatin-exposed TGCT cells that are similar to
the patterns reported for RA-induced differentiated TGCT
cells. We have identified genes that take part in apoptosis
signaling and terminal growth arrest. Cisplatin-induced
genes associated with terminal growth arrest or senescent-
like arrest were identified, indicating associations which
have not previously been proposed for TGCT cells. We
have also identified several p53 responsive genes and
microRNA target genes that may play important func-
tional roles. The differentially expressed genes are
expected to contribute to a better understanding of the
unusual sensitivity of testicular germ cell tumor cells to
some DNA-damaging agents.
Methods
Cell culture and treatment
The human testis cancer cell lines 833K and GCT27 were
generous gifts from Professor John R. W. Masters (Univer-
sity College London, UK). The 833K and GCT27 cells are
derived from human metastatic and primary embryonal
carcinoma, respectively [5,6] and a human colon cancer
cell line, HCT116 (ATCC-CCL-247, Manassas, VA).
The 833K and GCT27 cells were grown in cell culture
flasks (Corning Inc., USA) in RPMI 1640 medium with L-
glutamine (Cambrex, Belgium) supplemented with 10%
fetal bovine serum and 1% penicillin -streptomycin. The
HCT116 cells were maintained in McCoy's 5A medium
with L-glutamine (Cambrex, Belgium) supplemented
with 10% fetal calf serum and 1% penicillin-streptomy-
cin. All three cell lines were grown at 37°C in a humidi-
fied atmosphere of 5% of CO2 in air.
Cells were seeded in 100 mm cell culture dishes (Corning
Inc, USA) and allowed to attach 24 h prior to cisplatin
(Cis-Diamminedichloroplatinum(II) or CDDP, Sigma)
treatment. Cells in exponential growth phase were
exposed to cisplatin and harvested after 24 h and 48 h of
exposure and prepared for further analysis.
Cytotoxicity assay
Cells were exposed to cisplatin and their viability was
determined 24 h and 48 h after treatment with different
concentrations of cisplatin, by trypan blue exclusion and
flow cytometry (Argus 100, Skatron, Norway) at the time
RNA was harvested.
Gene expression measurements
RNA preparation
Total RNA was isolated from cisplatin treated and control
cell lines by GenElute kit (Sigma). RNA isolated from
three individual treatments was mixed. The quantity and
quality of isolated RNA was determined using a Nano-
Drop Spectrophotometer. RNA integrity was determined
by an Agilent 2100 Bioanalyzer (Agilent Technologies,
Palo Alto, CA). RNA from at least three independent
experiments was pooled before labeling and hybridiza-
tion to reduce possible bias of a single treatment.
Microarrays
21K human oligonucleotide microarrays were printed at
the Norwegian Microarray Consortium using OPERON
hum oligo v2.0. The microarrays consist of 70 mer, oligos
representing 21,329 genes from UniGene Database [74].
cDNA synthesis and labeling
Labeled cDNAs were synthesized according to the manu-
facturer's protocol, FairPlay cDNA labeling kit (Strata-
gene, La Jolla, CA). Briefly, 20 µg of total RNA (from
cisplatin treated or untreated control cell lines) in 13 µl of
nuclease-free water was combined with 1 µl of 500 ng/µl
oligo-d(T)12–18. The mixture was incubated at 70°C for 10
min and cooled on ice. For each reaction, 2 µl of 10×
StrataScript reaction buffer, 1 µl of unlabeled 20× dNTP
mix containing amino-allyl dUTP, 1.5 µl of 0.1 M dithio-
threitol and 0.5 µl of RNase Block (40 U/µl) were pre-
pared and mixed with the RNA sample and 1 µl of 50 U/
µl StrataScript RT. After incubation at 48°C for 30 min an
additional 1 µl of StrataScript RT was added and incuba-
tion was continued for 30 additional minutes. RNA was
degraded by adding 10 µl of 1 M NaOH, followed by a 10-
min incubation at 70°C, and the mixture neutralized with
10 µl of 1 M HCl. Unincorporated nucleotides were
removed by precipitation of the cDNA with 4 µl of 3 M
sodium acetate, 1 µl of 20 mg/ml glycogen and 100 µl ofPage 17 of 21
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washing the pellet with 70% ethanol, it was resuspended
in 5 µl of 2 × coupling buffer provided in the kit. Cy3
(untreated sample) or Cy5 (cisplatin treated sample) dye
(Amersham), resuspended in 45 µl of DMSO, was added
and the reaction incubated for 2 h at room temperature in
the dark. Dye-coupled cDNA was purified with a DNA-
binding spin cup, combined, and concentrated by vac-
uum drying.
Microarray hybridization and signal detection
Microarray slides were prehybridized in buffer containing
5× SSC, 1% Bovine Serum Albumin and 0.1% SDS at
42°C for 1 h to block nonspecific binding, and washed by
dipping several times in double distilled water. The slides
were then dipped in isopropanol and dried by centrifuga-
tion in 50 ml un-capped centrifuge tubes at 480 × g for 5
min.
Labeled cDNAs (combined Cy3 and Cy5 labeled cDNA)
were added to hybridization buffer (50% formamide, 5 ×
SSC, 0.1% SDS, 4 µg/µl yeast tRNA, and 0.6 µg/µl human
Cot-1 DNA), denatured for 5 min at 95°C, and applied to
the arrays underneath a cover slip (LifterSlip, Erie Scien-
tific). Arrays were placed in a hybridization chamber and
incubated overnight in a water bath at 42°C.
After hybridization, washing was performed as follows: 5
min washing with 2 × SSC, 0.1% SDS at 42°C, 10 min
washing with 0.1 × SSC, 0.1% SDS and 4 × 1 min washing
with 0.1 × SSC at room temperature. Slides were dried by
centrifugation at 480 × g for 5 min and scanned with an
Agilent microarray laser Scanner (Agilent, Palo Alto, CA).
Data analysis
In this study we have used time-matched pooled RNA
from untreated samples as a reference RNA. RNA from cis-
platin treated samples was always co-hybridized with the
reference RNA from the same cell line. Gene expression
levels are hence always relative to the untreated sample.
The microarray images were analyzed using the GenePix
4.1 image analysis software (Axon Instruments). This
included defining the spots, intensity calculation, flagging
spots with inadequate measurements, and subtracting
local background. Flagged spots were filtered out and nor-
malized using LOWESS normalization. All data filtering
and normalization was performed in J-Express Pro v 2.7
(MolMine, Bergen, Norway) [75]. Only those features that
passed quality assurance criteria were included in the
down-stream analysis. Missing values were estimated by
the k-nearest neighbor imputation (k = 15). The ratios of
the processed intensities of all genes and samples were
divided by the median of the ratios of three untreated
samples before log2 transformation. This was done to
facilitate the interpretation of the expression values. Rep-
licate data were averaged and used in all clustering. The
data generated from the arrays were deposited in NCBI
Gene Expression Omnibus (GEO), with following GEO
Series accession number: GSE7563 [76], according to the
Minimum Information About a Microarray Experiment
(MIAME) recommendations [77].
Identification of genes of interest
Genes with statistically significant changes in expression
before and after cisplatin treatment were identified using
SAM (Significance Analysis of Microarrays). SAM selects
significant genes based on differential expression between
sets of samples [45]. SAM gives estimates of the False Dis-
covery Rate (FDR), which is the proportion of genes likely
to have been wrongly identified by chance as being signif-
icant. The effect of multiple comparisons is controlled
through the FDR. It allows dynamically changing thresh-
olds for significance, through adjusting a threshold delta-
value. Different stringencies can be obtained by adjusting
the threshold delta, resulting in different numbers of
genes whose expression is classified as significantly
changed. We have used two-class, unpaired SAM analysis
to select genes whose mean expression level is signifi-
cantly differentially expressed between TGCT and
HCT116 cell lines.
Annotation and clustering
The genes (oligo probes) that were identified as statisti-
cally significant with SAM were further annotated using
the Norwegian Microarray Consortium Datawarehouse
(Unigene build # 197, Dec 01 2006) [26,27] and analyzed
for functional gene clusters by eGOn v2.0 [26,27] and
Panther [24,28]. The eGOn v2.0 uses Fisher's exact test to
determine whether, in any of the GO categories, the genes
of interest are over- or underrepresented compared to the
genes represented on the microarray [27]. Panther uses
the binomial statistics tool to determine over- or under-
representation of Panther classification categories. Pan-
ther determines functional clusters by representation of
individual genes in specific categories relative to all genes
in the same category on the array [24,28]. All hierarchical
clustering analysis and Principal Component Analysis
(PCA) were done by J-Express Pro v 2.7 [75]. PCA reduces
the dimensionality and classifies variables [78]. Hierarchi-
cal clustering analysis (average-linkage and Euclidean dis-
tance similarity measurement) was used to cluster
variables into groups based on their similarity, and the
results were visualized in a dendrogram.
Real time polymerase chain reaction (RT-PCR)
Validation of the expression of candidate genes identified
by microarray analysis was carried out by quantitative
real-time PCR using SYBR green chemistry. cDNA synthe-
sis was conducted using ABI High Capacity Archive Kit
(Applied Biosystems, Foster City, CA) from the same RNAPage 18 of 21
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time PCR was performed in 96 well PCR plates using the
Applied Biosystems Power SYBR® GREEN PCR master mix
and the 7500 Fast Real-Time PCR System (Applied Biosys-
tems, Foster City, CA, USA) according to the manufac-
turer's protocol; three independent measurements were
made for each gene of interest for each cDNA. The primer
sequences used to validate the microarray data are listed at
PrimerBank [79]. Thermo-cycling parameters were as fol-
lows: 95°C for 15 min; then 40 cycles of 95°C for 15 sec,
60°C for 60 sec, and 72°C for 35 sec to measure the fluo-
rescence signal; followed by the dissociation stage. Melt-
ing curves and quantitative analysis of the data, and the
average cycle threshold (Ct) measurement for the three
determinations, were used in calculations of relative
expression using 18S rRNA as the endogenous control in
the ∆∆Ct method (7500 System SDS software v1.3;
Applied Biosystems). The obtained fold change results
were log2-transformed. All reagents used in the real-time
PCR were purchased from Applied Biosystems.
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